Plus, news about Immuneering, Aditum Bio, Unicycive and X-Therma:
OcuTerra Therapeutics’ diabetic retinopathy drug fails PhII: The company’s RGD integrin inhibitor did not meet the primary endpoint of percentage of patients with a minimum two-step improvement in the diabetic retinopathy severity scale versus placebo. OcuTerra said it is reviewing the data to “evaluate the future” of the nesvategrast program. — Ayisha Sharma
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.